DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

Phase 2 Unknown 50 enrolled University Health Network, Toronto MOUNT SINAI HOSPITAL · collab Sunnybrook Health Sciences Centre · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function, renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in patients with T2D at high cardiovascular risk and non-T2D patients.

Timeline

Start: 2020-02-10
Primary completion: 2023-12
Completion: 2023-12

Outcome

Met primary endpoint

paper Dapagliflozin decreased vascular arterial stiffness, as measured by aortic augmentation index (placebo-adjusted change of -7.4±2.8%, P=0.01) after 12 weeks. PMID 41347301 ↗

Publications

Sridhar VS, Kugathasan L, Lytvyn Y, Deng Y, Liu H, Lovblom LE, Tse J, Nardone M, Floras JS, Osuntokun T, Tobushi T, Lam RCY, Lam B, Stevens J, Burger D, Touw DJ, Heerspink HJL, Lovshin JA, Perkins BA, Cherney DZI. Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension. 2026 Feb;83(2):e25955. doi: 10.1161/HYPERTENSIONAHA.125.25955. Epub 2025 Dec 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	—

Indications

No indication recorded.